Show simple item record

dc.contributor.authorMikell, I
dc.contributor.authorSather, D
dc.contributor.authorKalams, S
dc.contributor.authorAltfeld, Marcus
dc.contributor.authorStamatatos, L
dc.date.accessioned2011-03-25T16:14:29Z
dc.date.issued2009
dc.identifier.citationMikell, I., D. Sather, S. Kalams, Marcus Altfeld, and L. Stamatatos. 2009. P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection. Retrovirology 6(Suppl 3): P43.en_US
dc.identifier.issn1742-4690en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4774089
dc.description.abstractBackground: Determining how cross-reactive neutralizing antibody (NAb) responses develop during natural HIV-1 infection may provide key information to understand the role they play in controlling the infection and in disease progression. Here we investigated the frequency and breadth of broadly NAb responses during acute and early infection in a well controlled cohort, and attempted to characterize the factors associated with the development of such responses. Methods: The plasma of 38 clade B acutely-infected, antiretroviral-naive subjects from two cohorts was screened for breadth of neutralization against a panel of heterologous isolates in an Env pseudovirus neutralization assay. Clade A, B and C variants were chosen from reference panels of viruses, created to evaluate the NAb responses elicited during infection or immunization. Results: Our preliminary screening strategy demonstrated that broadly neutralizing antibodies can be detected in a third of the infected subjects. Breadth of neutralization can develop as early as one year during natural HIV infection, however the majority of breadth was observed at over two years post infection. Conclusion: Cross-reactive NAbs are developed more frequently during early infection than previously thought. The consequences of this 'early' development of cross-reactive NAbs on plasma viremia and disease progression are under investigation. The work described was supported by National Institute of Health grant number R01 AI047708-11.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi:10.1186/1742-4690-6-S3-P43en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767944/pdf/en_US
dash.licenseLAA
dc.titleP04-15. Prevalence of Broadly Neutralizing Antibody Responses During Acute/Early HIV Infectionen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalRetrovirologyen_US
dash.depositing.authorAltfeld, Marcus
dc.date.available2011-03-25T16:14:29Z
dash.affiliation.otherHMS^Medicine-Massachusetts General Hospitalen_US
dc.identifier.doi10.1186/1742-4690-6-S3-P43*
dash.contributor.affiliatedAltfeld, Marcus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record